Overview
The study is aimed to test the performance of a simple, easy, reproducible cytofluorimetric assay to complement imaging studies for:
- predicting response to immune-therapeutic regimens in HCC in the early phase of treatment,
- to rule out pseudo-progression,
- to early predict the escape from effectiveness of treatment.
Description
- To assess the accuracy of biomarkers from an immunophenotypic test (CD8+, PD1+,
PD-L1+, CTLA4+, LAG3+, CD8+PD1+, CD8+PDL1+ peripheral lymphocyte populations and
circulating granulocytes) in predicting the response to immuno-therapy in patients
affected by hepatocellular carcinoma (HCC).
- To compare the transcriptomic signatures of peripheral blood mononuclear cells (PBMC) of responders and non-responders (assessed at the first imaging study).
RNAseq data will be validated by RT-PCR in independent prospective cohorts.
Eligibility
Inclusion Criteria:
- age ≥ 18 years
- diagnosis of HCC
- execution of laboratory tests and subsequent treatments and follow-up at our center.
- obtained written informed consent to the study participation
Exclusion Criteria:
- immune-related concomitant diseases
- HIV infection